+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 100Years
All Genders
ID04086485

Study of Lu-177-DOTATATE and Olaparib Combination in Patients with Inoperable Gastroenteropancreatic Neuroendocrine Tumors Evaluating Safety and Tumor Response

Led by National Cancer Institute (NCI) · Updated on 2026-10-16

56

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating a rare type of tumor called neuroendocrine tumors NETs, which can arise in the gastrointestinal tract and pancreas. This study focuses on patients with inoperable NETs that express somatostatin receptors. The goal is to evaluate whether a combination of two drugs, Lutathera and Olaparib, can be safely given together and whether this treatment can shrink these tumors. The study is a phase III clinical trial conducted to assess safety, tolerability, and effectiveness. Participants will receive Lutathera intravenously every 8 weeks for a total of 4 cycles. Each cycle includes oral Olaparib taken twice daily for 4 weeks, starting 2 days before the Lutathera infusion. An amino acid infusion is also administered to protect the kidneys during treatment. Patients will be monitored closely with physical exams, blood and urine tests, heart function tests, and imaging scans including PETCT scans using radioactive tracers. The study includes dose escalation of Olaparib in phase I to find the maximum tolerated dose, followed by phase II treatment at that dose. Throughout the study, participants will attend regular clinic visits for evaluation and toxicity assessments, including follow-up visits 4 weeks after treatment ends, then every 12 weeks for 3 years, and yearly phone calls thereafter. Researchers will measure outcomes such as maximum tolerated dose, tumor response rates, progression-free survival, and overall survival. Participants will also complete questionnaires about their well-being and function to help assess treatment impact and safety over time.

CONDITIONS

Brief Title

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Research Team

J

Joy H Zou, R.N.

F

Frank I Lin, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here